Cofactor Genomics OncoPrism for Colorectal, Breast, Bladder, and Kidney Cancer

Cofactor Genomics has launched OncoPrism genomic classifiers for colorectal, breast, bladder, and kidney cancer. The new products build on the company's OncoPrism classifier, which received a positive coverage decision in October from Medicare administrative contractor Palmetto GBA. The four new cancer profiles also follow the clinical validation and launch of OncoPrism-NSCLC for non-small cell lung cancer. In general, OncoPrism tests evaluate a patient's tumor immune profile against Cofactor's high-dimensional RNA-based Health Expression Models to predict a patient's response to immune checkpoint inhibitor (ICI) immunotherapy, classifying patients into low, medium, and high groups. In addition, OncoPrism can be used for patient stratification and subtyping in studies and clinical trials, the company said.